Loratadine: Pediatric drug information

(For additional information see "Loratadine: Drug information" and see "Loratadine: Patient drug information")

For abbreviations, symbols, and age group definitions used in Lexicomp (show table)

Brand Names: US

Alavert [OTC];
Allergy Relief (Loratadine) [OTC];
Allergy Relief Loratadine [OTC] [DSC];
Allergy Relief [OTC];
Childrens Loratadine [OTC];
Claritin Allergy Childrens [OTC];
Claritin Childrens [OTC];
Claritin Reditabs [OTC];
Claritin [OTC];
FT All Day Allergy Relief [OTC];
FT Allergy Childrens [OTC];
FT Allergy Relief Childrens [OTC];
GoodSense Allergy Relief [OTC];
Loradamed [OTC];
Loratadine Childrens [OTC];
Triaminic Allerchews [OTC]

Therapeutic Category

Antihistamine

Dosing: Pediatric

Allergic symptoms, hay fever

Allergic symptoms, hay fever:

General dosing:

Children ≥2 to <6 years: Oral: 5 mg once daily.

Children ≥6 years and Adolescents: 5 mg twice daily or 10 mg once daily.

Product-specific dosing:

Children ≥2 to <6 years: Oral: Oral liquid or chewable tablet: 5 mg once daily.

Children ≥6 years and Adolescents: Oral:

Oral liquid, capsule, tablet, or chewable tablet: 10 mg once daily.

Dispersible tablet: 5 mg twice daily or 10 mg once daily.

Urticaria, chronic spontaneous

Urticaria, chronic spontaneous (idiopathic): Limited data available (Kliegman 2020; Pozzo-Magaña 2017): Note: Considered first-line therapy for management of chronic urticaria; if response inadequate after 2 to 4 weeks of therapy or symptoms intolerable, consider increasing the dose of loratadine (as age and weight permits) as second-line treatment rather than changing therapy (Zuberbier 2018).

Children ≥2 to <6 years: Oral: 5 mg once daily.

Children ≥6 years and Adolescents: Oral: 10 mg once daily.

Dosing: Kidney Impairment: Pediatric

There are no dosage adjustments provided in manufacturer's labeling, however, the following recommendations have been recommended (Aronoff 2007):

Children ≥2 years and Adolescents: No dosage adjustment necessary for any degree of renal impairment.

Dosing: Hepatic Impairment: Pediatric

There are no dosage adjustments provided in manufacturer's labeling.

Dosing: Adult

(For additional information see "Loratadine: Drug information")

Allergic rhinitis or conjunctivitis

Allergic rhinitis or conjunctivitis: Oral: 10 mg once daily or 5 mg twice daily.

OTC labeling (patient-guided therapy for symptoms of hay fever or other upper respiratory allergies): Oral: 10 mg once daily or 5 mg twice daily; maximum dose: 10 mg/day.

Urticaria, new onset and chronic spontaneous

Urticaria, new onset and chronic spontaneous:

New onset: Oral: Initial: 10 mg once daily. If symptom control is inadequate, may immediately increase to 10 mg twice daily (Asero 2021).

Chronic spontaneous: Oral: Initial: 10 mg once daily. If symptom control is inadequate after 1 to 4 weeks, may increase to 10 mg twice daily. Although current guidelines state that antihistamine doses may be increased up to 4 times the standard dose (eg, to 20 mg twice daily), there is limited evidence for greater efficacy with this dose of loratadine, and other antihistamines are preferred. Periodically reevaluate necessity for continued treatment (EAACI [Zuberbier 2018]; Khan 2021).

Dosing: Kidney Impairment: Adult

The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.

Note: Renally adjusted dose recommendations are based on a usual dose of 10 mg/day.

Altered kidney function:

Oral:

CrCl ≥30 mL/minute: No dosage adjustment necessary (Matzke 1990; manufacturer's labeling).

CrCl <30 mL/minute: 10 mg every 48 hours (Matzke 1990; expert opinion; manufacturer's labeling).

Hemodialysis, intermittent (thrice weekly): Not dialyzable (Matzke 1990): Oral: 10 mg every 48 hours (Matzke 1990; expert opinion).

Peritoneal dialysis: Unlikely to be significantly dialyzable (large V_d, highly protein bound): Oral: 10 mg every 48 hours (expert opinion).

CRRT:

Note: Drug clearance is dependent on the effluent flow rate, filter type, and method of renal replacement. Recommendations are based on high-flux dialyzers and effluent flow rates of 20 to 25 mL/kg/hour (or ~1,500 to 3,000 mL/hour) unless otherwise noted.

Oral: 10 mg every 48 hours (expert opinion).

PIRRT (eg, sustained, low-efficiency diafiltration):

Note: Drug clearance is dependent on the effluent flow rate, filter type, and method of renal replacement.

Oral: 10 mg every 48 hours (expert opinion).

Dosing: Hepatic Impairment: Adult

No dosage adjustment provided in manufacturer’s labeling; however, hepatic impairment increases systemic exposure to loratadine.

Adverse Reactions

The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse reactions reported in adults and pediatric patients unless otherwise indicated.

>10%: Nervous system: Headache (adolescents and adults: 12%)

1% to 10%:

Cardiovascular: Chest pain (<2%), flushing (<2%), hypertension (<2%), hypotension (<2%), palpitations (<2%), supraventricular tachycardia (<2%), syncope (<2%), tachycardia (<2%)

Dermatologic: Dermatitis (<2%), diaphoresis (<2%), dry hair (<2%), pruritus (<2%), skin photosensitivity (<2%), skin rash (children: 2% to 3%), xeroderma (<2%)

Endocrine & metabolic: Decreased libido (<2%), heavy menstrual bleeding (<2%), increased thirst (<2%), weight gain (<2%)

Gastrointestinal: Abdominal pain (children: 2%), altered salivation (<2%), anorexia (<2%), constipation (<2%), diarrhea (children: 2% to 3%), dysgeusia (<2%), dyspepsia (<2%), flatulence (<2%), gastritis (<2%), hiccups (<2%), increased appetite (<2%), loose stools (<2%), nausea (<2%), stomatitis (children: 2% to 3%), vomiting (<2%), xerostomia (adolescents and adults: 3%)

Genitourinary: Altered micturition (<2%), dysmenorrhea (<2%), impotence (<2%), mastalgia (<2%), urinary incontinence (<2%), urinary retention (<2%), urine discoloration (<2%), vaginitis (<2%)

Hematologic & oncologic: Purpuric disease (<2%)

Hypersensitivity: Angioedema (<2%)

Infection: Viral infection (children: 2% to 3%)

Nervous system: Agitation (<2%), amnesia (<2%), anxiety (<2%), confusion (<2%), depression (<2%), dizziness (<2%), drowsiness (adolescents and adults: 8%), fatigue (2% to 4%), hypertonia (<2%), hypoesthesia (<2%), insomnia (<2%), irritability (<2%), lack of concentration (<2%), malaise (children: 2%), migraine (<2%), nervousness (children: 4%), nightmares (<2%), paresthesia (<2%), rigors (<2%), vertigo (<2%), voice disorder (children: 2%)

Neuromuscular & skeletal: Arthralgia (<2%), asthenia (<2%), back pain (<2%), hyperkinetic muscle activity (children: 3%), lower limb cramp (<2%), myalgia (<2%), tremor (<2%)

Ophthalmic: Blepharospasm (<2%), blurred vision (<2%), conjunctivitis (children: 2%), eye pain (<2%)

Otic: Otalgia (children: 2% to 3%), tinnitus (<2%)

Respiratory: Bronchitis (<2%), bronchospasm (<2%), cough (<2%), dry nose (<2%), dyspnea (<2%), epistaxis (children: 2% to 3%), flu-like symptoms (children: 2% to 3%), hemoptysis (<2%), laryngitis (<2%), pharyngitis (children: 2% to 3%), upper respiratory tract infection (children: 2%), wheezing (children: 4%)

Miscellaneous: Fever (<2%)

Postmarketing:

Cardiovascular: Peripheral edema

Dermatologic: Alopecia, erythema multiforme

Genitourinary: Breast hypertrophy

Hematologic & oncologic: Thrombocytopenia

Hepatic: Abnormal liver function, hepatic necrosis, hepatitis, jaundice

Hypersensitivity: Anaphylaxis

Nervous system: Seizure

Contraindications

Hypersensitivity to loratadine or any component of the formulation

Warnings/Precautions

Disease-related concerns:

• Hepatic impairment: Hepatic impairment increases systemic exposure. Use with caution.

• Renal impairment: Use with caution in patients with renal impairment.

Concurrent drug therapy issues:

• Sedatives: Effects may be potentiated when used with other sedative drugs or ethanol.

Dosage form specific issues:

• Benzyl alcohol and derivatives: Some dosage forms may contain sodium benzoate/benzoic acid; benzoic acid (benzoate) is a metabolite of benzyl alcohol; large amounts of benzyl alcohol (≥99 mg/kg/day) have been associated with a potentially fatal toxicity (“gasping syndrome”) in neonates; the “gasping syndrome” consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP ["Inactive" 1997]; CDC, 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors, 2001); avoid or use dosage forms containing benzyl alcohol derivative with caution in neonates. See manufacturer’s labeling.

• Phenylalanine: Some products may contain phenylalanine.

Warnings: Additional Pediatric Considerations

Safety and efficacy for the use of cough and cold products in pediatric patients <4 years of age is limited; the AAP warns against the use of these products for respiratory illnesses in young children. Serious adverse effects including death have been reported. Many of these products contain multiple active ingredients, increasing the risk of accidental overdose when used with other products. The FDA does not recommend OTC uses for these products in pediatric patients <2 years of age and recommends to use with caution in pediatric patients ≥2 years of age. Health care providers are reminded to ask caregivers about the use of OTC cough and cold products in order to avoid exposure to multiple medications containing the same ingredient (AAP 2018; CDC 2007; FDA 2017; FDA 2018).

Dosage Forms: US

Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product

Capsule, Oral:

Claritin: 10 mg [contains fd&c blue #1 (brilliant blue)]

GoodSense Allergy Relief: 10 mg [contains fd&c blue #1 (brilliant blue)]

Generic: 10 mg

Solution, Oral:

Childrens Loratadine: 5 mg/5 mL (120 mL) [fruit flavor]

Childrens Loratadine: 5 mg/5 mL (120 mL) [alcohol free, dye free; contains propylene glycol, sodium benzoate, sodium metabisulfite; grape flavor]

Childrens Loratadine: 5 mg/5 mL (120 mL) [alcohol free, dye free, sugar free; contains propylene glycol, sodium benzoate; grape flavor]

Claritin Allergy Childrens: 5 mg/5 mL (240 mL) [alcohol free, dye free, sugar free; contains edetate (edta) disodium, propylene glycol, sodium benzoate, sorbitol]

FT Allergy Childrens: 5 mg/5 mL (120 mL) [alcohol free, dye free; contains propylene glycol, sodium benzoate, sodium metabisulfite; peach flavor]

FT Allergy Childrens: 5 mg/5 mL (120 mL) [alcohol free, dye free, sugar free; contains polyethylene glycol (macrogol), propylene glycol, sodium benzoate; grape flavor]

Loratadine Childrens: 5 mg/5 mL (120 mL) [alcohol free, dye free, gluten free, sugar free; contains edetate (edta) disodium, propylene glycol, sodium benzoate; grape flavor]

Loratadine Childrens: 5 mg/5 mL (120 mL, 240 mL) [alcohol free, dye free, sugar free; contains edetate (edta) disodium dihydrate, propylene glycol, sodium benzoate; grape flavor]

Loratadine Childrens: 5 mg/5 mL (10 mL [DSC]) [alcohol free, dye free, sugar free; contains propylene glycol, sodium benzoate; grape flavor]

Loratadine Childrens: 5 mg/5 mL (120 mL) [sugar free; contains polyethylene glycol (macrogol), propylene glycol, sodium benzoate, sodium metabisulfite; grape flavor]

Generic: 5 mg/5 mL (120 mL)

Tablet, Oral:

Allergy Relief: 10 mg

Allergy Relief: 10 mg [contains corn starch]

Allergy Relief: 10 mg [gluten free]

Allergy Relief (Loratadine): 10 mg

Allergy Relief (Loratadine): 10 mg [contains corn starch]

Allergy Relief Loratadine: 10 mg [DSC]

Claritin: 10 mg

FT All Day Allergy Relief: 10 mg [gluten free]

Loradamed: 10 mg

Generic: 10 mg

Tablet Chewable, Oral:

Claritin: 5 mg [contains aspartame, fd&c blue #2 (indigo carm) aluminum lake; grape flavor]

Claritin Childrens: 5 mg [contains aspartame, carmine; bubble-gum flavor]

FT Allergy Relief Childrens: 5 mg [contains aspartame, fd&c blue #2 (indigo carm) aluminum lake; grape flavor]

Loratadine Childrens: 5 mg [contains aspartame; bubble-gum flavor]

Loratadine Childrens: 5 mg [dye free; contains aspartame; bubble-gum flavor]

Tablet Disintegrating, Oral:

Alavert: 10 mg [contains aspartame]

Alavert: 10 mg [DSC] [contains aspartame; citrus flavor]

Claritin Reditabs: 5 mg, 10 mg

Triaminic Allerchews: 10 mg

Generic: 10 mg

Generic Equivalent Available: US

Yes

Pricing: US

Capsules (Claritin Oral)

10 mg (per each): $1.19

Capsules (Loratadine Oral)

10 mg (per each): $1.76

Chewable (Claritin Childrens Oral)

5 mg (per each): $0.80

Chewable (Claritin Oral)

5 mg (per each): $1.24

Solution (Claritin Allergy Childrens Oral)

5 mg/5 mL (per mL): $0.07

Solution (Loratadine Oral)

5 mg/5 mL (per mL): $0.05 - $0.07

Tablet, orally-disintegrating (Claritin Reditabs Oral)

5 mg (per each): $0.92

10 mg (per each): $1.06

Tablet, orally-disintegrating (Loratadine Oral)

10 mg (per each): $0.93 - $1.26

Tablet, orally-disintegrating (Triaminic Allerchews Oral)

10 mg (per each): $0.64

Tablets (Claritin Oral)

10 mg (per each): $0.75

Tablets (Loratadine Oral)

10 mg (per each): $0.04 - $0.86

Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.

Administration: Pediatric

Oral: Administer without regard to meals.

Rapidly disintegrating tablet: Place rapidly disintegrating tablet on the tongue; tablet disintegration occurs rapidly; may administer with or without water.

Administration: Adult

May be administered without regard to meals.

Dispersible tablet: Place in mouth and allow to dissolve. Swallow with or without water.

Storage/Stability

Store at 20°C to 25°C (68°F to 77°F).

Rapidly-disintegrating tablets: Use within 6 months of opening foil pouch, and immediately after opening individual tablet blister. Store in a dry place.

Use

Treatment of symptoms of hay fever or other upper respiratory allergies (OTC product: FDA approved in ages ≥2 years and adults); has also been used for the treatment of chronic idiopathic urticaria.

Medication Safety Issues

Sound-alike/look-alike issues:

Claritin may be confused with Clarispray, Claritin Eye (ketotifen), clarithromycin

Metabolism/Transport Effects

Substrate of CYP2D6 (minor), CYP3A4 (minor), P-glycoprotein/ABCB1 (minor); Note: Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential

Drug Interactions

Note: Interacting drugs may not be individually listed below if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed). For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.

Acetylcholinesterase Inhibitors: May diminish the therapeutic effect of Anticholinergic Agents. Anticholinergic Agents may diminish the therapeutic effect of Acetylcholinesterase Inhibitors. Risk C: Monitor therapy

Aclidinium: May enhance the anticholinergic effect of Anticholinergic Agents. Risk X: Avoid combination

Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl). Risk C: Monitor therapy

Alizapride: May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy

Amantadine: May enhance the anticholinergic effect of Anticholinergic Agents. Risk C: Monitor therapy

Amezinium: Antihistamines may enhance the stimulatory effect of Amezinium. Risk C: Monitor therapy

Amiodarone: May increase the serum concentration of Loratadine. Management: Due to reported QT interval prolongation and Torsades de Pointes with this combination, consider an alternative to loratadine when possible. If concomitant use cannot be avoided, monitor QT interval and for signs of dyshythmias (eg, syncope). Risk D: Consider therapy modification

Anticholinergic Agents: May enhance the adverse/toxic effect of other Anticholinergic Agents. Risk C: Monitor therapy

Azelastine (Nasal): May enhance the CNS depressant effect of CNS Depressants. Risk X: Avoid combination

Benzylpenicilloyl Polylysine: Antihistamines may diminish the diagnostic effect of Benzylpenicilloyl Polylysine. Management: Suspend systemic H1 antagonists for benzylpenicilloyl-polylysine skin testing and delay testing until systemic antihistaminic effects have dissipated. A histamine skin test may be used to assess persistent antihistaminic effects. Risk D: Consider therapy modification

Betahistine: Antihistamines may diminish the therapeutic effect of Betahistine. Betahistine may diminish the therapeutic effect of Antihistamines. Risk C: Monitor therapy

Blonanserin: CNS Depressants may enhance the CNS depressant effect of Blonanserin. Management: Use caution if coadministering blonanserin and CNS depressants; dose reduction of the other CNS depressant may be required. Strong CNS depressants should not be coadministered with blonanserin. Risk D: Consider therapy modification

Botulinum Toxin-Containing Products: May enhance the anticholinergic effect of Anticholinergic Agents. Risk C: Monitor therapy

Brexanolone: CNS Depressants may enhance the CNS depressant effect of Brexanolone. Risk C: Monitor therapy

Brimonidine (Topical): May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy

Bromopride: May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy

Bromperidol: May enhance the CNS depressant effect of CNS Depressants. Risk X: Avoid combination

Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine. Management: Consider reduced doses of other CNS depressants, and avoiding such drugs in patients at high risk of buprenorphine overuse/self-injection. Initiate buprenorphine at lower doses in patients already receiving CNS depressants. Risk D: Consider therapy modification

Cannabinoid-Containing Products: Anticholinergic Agents may enhance the tachycardic effect of Cannabinoid-Containing Products. Risk C: Monitor therapy

Cannabinoid-Containing Products: CNS Depressants may enhance the CNS depressant effect of Cannabinoid-Containing Products. Risk C: Monitor therapy

Chloral Betaine: May enhance the adverse/toxic effect of Anticholinergic Agents. Risk C: Monitor therapy

Chlormethiazole: May enhance the CNS depressant effect of CNS Depressants. Management: Monitor closely for evidence of excessive CNS depression. The chlormethiazole labeling states that an appropriately reduced dose should be used if such a combination must be used. Risk D: Consider therapy modification

Chlorphenesin Carbamate: May enhance the adverse/toxic effect of CNS Depressants. Risk C: Monitor therapy

Chlorprothixene: Anticholinergic Agents may enhance the anticholinergic effect of Chlorprothixene. Risk C: Monitor therapy

Cimetropium: Anticholinergic Agents may enhance the anticholinergic effect of Cimetropium. Risk X: Avoid combination

CloZAPine: Anticholinergic Agents may enhance the constipating effect of CloZAPine. Management: Consider alternatives to this combination whenever possible. If combined, monitor closely for signs and symptoms of gastrointestinal hypomotility and consider prophylactic laxative treatment. Risk D: Consider therapy modification

CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants. Risk C: Monitor therapy

Daridorexant: May enhance the CNS depressant effect of CNS Depressants. Management: Dose reduction of daridorexant and/or any other CNS depressant may be necessary. Use of daridorexant with alcohol is not recommended, and the use of daridorexant with any other drug to treat insomnia is not recommended. Risk D: Consider therapy modification

DexmedeTOMIDine: CNS Depressants may enhance the CNS depressant effect of DexmedeTOMIDine. Management: Monitor for increased CNS depression during coadministration of dexmedetomidine and CNS depressants, and consider dose reductions of either agent to avoid excessive CNS depression. Risk D: Consider therapy modification

Difelikefalin: May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy

Dimethindene (Topical): May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy

Doxylamine: CNS Depressants may enhance the CNS depressant effect of Doxylamine. Risk C: Monitor therapy

DroPERidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (eg, opioids, barbiturates) with concomitant use. Risk D: Consider therapy modification

Eluxadoline: Anticholinergic Agents may enhance the constipating effect of Eluxadoline. Risk X: Avoid combination

Esketamine: May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy

Flunarizine: CNS Depressants may enhance the CNS depressant effect of Flunarizine. Risk X: Avoid combination

Flunitrazepam: CNS Depressants may enhance the CNS depressant effect of Flunitrazepam. Management: Reduce the dose of CNS depressants when combined with flunitrazepam and monitor patients for evidence of CNS depression (eg, sedation, respiratory depression). Use non-CNS depressant alternatives when available. Risk D: Consider therapy modification

Gastrointestinal Agents (Prokinetic): Anticholinergic Agents may diminish the therapeutic effect of Gastrointestinal Agents (Prokinetic). Risk C: Monitor therapy

Glucagon: Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased. Risk C: Monitor therapy

Glycopyrrolate (Oral Inhalation): Anticholinergic Agents may enhance the anticholinergic effect of Glycopyrrolate (Oral Inhalation). Risk X: Avoid combination

Glycopyrronium (Topical): May enhance the anticholinergic effect of Anticholinergic Agents. Risk X: Avoid combination

Hyaluronidase: Antihistamines may diminish the therapeutic effect of Hyaluronidase. Risk C: Monitor therapy

HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants. Management: Consider a decrease in the CNS depressant dose, as appropriate, when used together with hydroxyzine. Increase monitoring of signs/symptoms of CNS depression in any patient receiving hydroxyzine together with another CNS depressant. Risk D: Consider therapy modification

Ipratropium (Oral Inhalation): May enhance the anticholinergic effect of Anticholinergic Agents. Risk X: Avoid combination

Itopride: Anticholinergic Agents may diminish the therapeutic effect of Itopride. Risk C: Monitor therapy

Ixabepilone: May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy

Kava Kava: May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy

Ketoconazole (Systemic): May increase the serum concentration of Loratadine. Risk C: Monitor therapy

Kratom: May enhance the CNS depressant effect of CNS Depressants. Risk X: Avoid combination

Lemborexant: May enhance the CNS depressant effect of CNS Depressants. Management: Dosage adjustments of lemborexant and of concomitant CNS depressants may be necessary when administered together because of potentially additive CNS depressant effects. Close monitoring for CNS depressant effects is necessary. Risk D: Consider therapy modification

Levosulpiride: Anticholinergic Agents may diminish the therapeutic effect of Levosulpiride. Risk X: Avoid combination

Lisuride: May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy

Lofexidine: May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy

Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy

Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants. Management: Reduce the usual dose of CNS depressants by 50% if starting methotrimeprazine until the dose of methotrimeprazine is stable. Monitor patient closely for evidence of CNS depression. Risk D: Consider therapy modification

Metoclopramide: May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy

MetyroSINE: CNS Depressants may enhance the sedative effect of MetyroSINE. Risk C: Monitor therapy

Mianserin: May enhance the anticholinergic effect of Anticholinergic Agents. Risk C: Monitor therapy

Minocycline (Systemic): May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy

Mirabegron: Anticholinergic Agents may enhance the adverse/toxic effect of Mirabegron. Risk C: Monitor therapy

Nabilone: May enhance the CNS depressant effect of CNS Depressants. Risk X: Avoid combination

Nitroglycerin: Anticholinergic Agents may decrease the absorption of Nitroglycerin. Specifically, anticholinergic agents may decrease the dissolution of sublingual nitroglycerin tablets, possibly impairing or slowing nitroglycerin absorption. Risk C: Monitor therapy

Olopatadine (Nasal): May enhance the CNS depressant effect of CNS Depressants. Risk X: Avoid combination

Opioid Agonists: CNS Depressants may enhance the CNS depressant effect of Opioid Agonists. Management: Avoid concomitant use of opioid agonists and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug. Risk D: Consider therapy modification

Orphenadrine: CNS Depressants may enhance the CNS depressant effect of Orphenadrine. Risk X: Avoid combination

Oxatomide: May enhance the anticholinergic effect of Anticholinergic Agents. Risk X: Avoid combination

Oxomemazine: May enhance the CNS depressant effect of CNS Depressants. Risk X: Avoid combination

Oxybate Salt Products: CNS Depressants may enhance the CNS depressant effect of Oxybate Salt Products. Management: Consider alternatives to this combination when possible. If combined, dose reduction or discontinuation of one or more CNS depressants (including the oxybate salt product) should be considered. Interrupt oxybate salt treatment during short-term opioid use Risk D: Consider therapy modification

OxyCODONE: CNS Depressants may enhance the CNS depressant effect of OxyCODONE. Management: Avoid concomitant use of oxycodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug. Risk D: Consider therapy modification

Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde. Risk X: Avoid combination

Perampanel: May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy

Piribedil: CNS Depressants may enhance the CNS depressant effect of Piribedil. Risk C: Monitor therapy

Pitolisant: Antihistamines may diminish the therapeutic effect of Pitolisant. Risk X: Avoid combination

Potassium Chloride: Anticholinergic Agents may enhance the ulcerogenic effect of Potassium Chloride. Management: Patients on drugs with substantial anticholinergic effects should avoid using any solid oral dosage form of potassium chloride. Risk X: Avoid combination

Potassium Citrate: Anticholinergic Agents may enhance the ulcerogenic effect of Potassium Citrate. Management: Patients on drugs with substantial anticholinergic effects should avoid using any solid oral dosage form of potassium citrate. Risk X: Avoid combination

Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole. Risk C: Monitor therapy

Pramlintide: May enhance the anticholinergic effect of Anticholinergic Agents. These effects are specific to the GI tract. Risk X: Avoid combination

Procarbazine: May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy

Ramosetron: Anticholinergic Agents may enhance the constipating effect of Ramosetron. Risk C: Monitor therapy

Revefenacin: Anticholinergic Agents may enhance the anticholinergic effect of Revefenacin. Risk X: Avoid combination

Rivastigmine: Anticholinergic Agents may diminish the therapeutic effect of Rivastigmine. Rivastigmine may diminish the therapeutic effect of Anticholinergic Agents. Management: Use of rivastigmine with an anticholinergic agent is not recommended unless clinically necessary. If the combination is necessary, monitor for reduced anticholinergic effects. Risk D: Consider therapy modification

Ropeginterferon Alfa-2b: CNS Depressants may enhance the adverse/toxic effect of Ropeginterferon Alfa-2b. Specifically, the risk of neuropsychiatric adverse effects may be increased. Management: Avoid coadministration of ropeginterferon alfa-2b and other CNS depressants. If this combination cannot be avoided, monitor patients for neuropsychiatric adverse effects (eg, depression, suicidal ideation, aggression, mania). Risk D: Consider therapy modification

ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole. Risk C: Monitor therapy

Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine. Risk C: Monitor therapy

Rufinamide: May enhance the adverse/toxic effect of CNS Depressants. Specifically, sleepiness and dizziness may be enhanced. Risk C: Monitor therapy

Secretin: Anticholinergic Agents may diminish the therapeutic effect of Secretin. Management: Avoid concomitant use of anticholinergic agents and secretin. Discontinue anticholinergic agents at least 5 half-lives prior to administration of secretin. Risk D: Consider therapy modification

Suvorexant: CNS Depressants may enhance the CNS depressant effect of Suvorexant. Management: Dose reduction of suvorexant and/or any other CNS depressant may be necessary. Use of suvorexant with alcohol is not recommended, and the use of suvorexant with any other drug to treat insomnia is not recommended. Risk D: Consider therapy modification

Thalidomide: CNS Depressants may enhance the CNS depressant effect of Thalidomide. Risk X: Avoid combination

Thiazide and Thiazide-Like Diuretics: Anticholinergic Agents may increase the serum concentration of Thiazide and Thiazide-Like Diuretics. Risk C: Monitor therapy

Tiotropium: Anticholinergic Agents may enhance the anticholinergic effect of Tiotropium. Risk X: Avoid combination

Topiramate: Anticholinergic Agents may enhance the adverse/toxic effect of Topiramate. Risk C: Monitor therapy

Trimeprazine: May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy

Umeclidinium: May enhance the anticholinergic effect of Anticholinergic Agents. Risk X: Avoid combination

Valerian: May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy

Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem. Management: Reduce the Intermezzo brand sublingual zolpidem adult dose to 1.75 mg for men who are also receiving other CNS depressants. No such dose change is recommended for women. Avoid use with other CNS depressants at bedtime; avoid use with alcohol. Risk D: Consider therapy modification

Zuranolone: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to the use of zuranolone with other CNS depressants or alcohol. If combined, consider a zuranolone dose reduction and monitor patients closely for increased CNS depressant effects. Risk D: Consider therapy modification

Food Interactions

Food increases bioavailability and delays peak. Management: Administer without regard to meals.

Dietary Considerations

May be taken without regard to meals. Some products may contain phenylalanine and/or sodium.

Pregnancy Considerations

Guidelines for the use of antihistamines in the treatment of allergic rhinitis or urticaria in pregnancy are generally the same as in nonpregnant females. Loratadine may be used when a second generation antihistamine is needed. The lowest effective dose should be used (BSACI [Powell 2015]; BSACI [Scadding 2017]; Zuberbier 2018).

Monitoring Parameters

Improvement in signs and symptoms of allergic rhinitis or chronic idiopathic urticaria.

Mechanism of Action

Long-acting tricyclic antihistamine with selective peripheral histamine H₁-receptor antagonistic properties

Pharmacokinetics (Adult Data Unless Noted)

Note: The pharmacokinetic profile of children 2 to 12 years is similar to that of adults (Claritin prescribing information 2000)

Onset of action: 1-3 hours (Claritin prescribing information 2000)

Peak effect: 8-12 hours (Claritin prescribing information 2000)

Duration: >24 hours (Claritin prescribing information 2000)

Absorption: Rapid; food increases total bioavailability (AUC) by 40% to 48% (Claritin prescribing information 2000)

Distribution: V_d: 119 L/kg (Haria 1994); binds preferentially to peripheral nervous system H₁ receptors; no appreciable entry into CNS (Claritin prescribing information 2000)

Protein binding: 97% to 99% (loratadine), 73% to 76% (metabolite) (Haria 1994)

Metabolism: Extensively hepatic via CYP2D6 and 3A4 to active metabolite (descarboethoxyloratadine) (Claritin prescribing information 2000)

Half-life elimination: 8.4 hours (range: 3 to 20 hours) (loratadine), 28 hours (range: 8.8 to 92 hours) (metabolite) (Claritin prescribing information 2000); hepatic impairment: 24 hours (loratadine), 37 hours (metabolite) (Claritin prescribing information 2000)

Time to peak, serum: Loratadine: 1.3 hours (loratadine), 2.3 hours (metabolite) (Claritin prescribing information 2000)

Excretion: Urine (40%) and feces (40%) as metabolites

Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)

Altered kidney function: With CrCl <30 mL/minute, AUC and C_max are increased approximately 73% for loratadine and 120% for its metabolite.

Hepatic function impairment: AUC and C_max doubled for loratadine

Older adult: AUC and C_max are increased approximately 50%, and t_½ ranged from 6.7 to 37 hours

Brand Names: International

International Brand Names by Country

For country code abbreviations (show table)

(AE) United Arab Emirates: Clara | Claritin kids | Claritine | Emilora | Klarfast | Lohist | Loracare | Loradad | Loraday | Lorahist | Loralife | Lorano | Loratin | Lorine | Lorine fm | Mosedin | Neoday | Restamine | Roletra | Tectaler | Tidilor;
(AR) Argentina: Aerotina | Alergiano | Alergitrat L | Alermuc | Alerpriv | Antialergico | Aparzo | Bedix | Benadryl 24 Flash | Biloina | Clarityne | Devedryl | Dexitis | Hisplex | Lertamine | Liberol flash | Lisaler | Loisan | Loratadina | Loratadina Fabra | Loratadina Gezzi | Loratadina ilab | Loratadina indeco | Loratadina northia | Loratadina tauro | Loratadina vannier | Loratex | Loratine | Mudantil L | Nastizol antialergico | Negalerg | Nularef | Omega 100 l | Predual l | Primer nivel | Pulmosan Aller | Refenax Antialergico | Ronedina | Sinaler | Tabcin alergia | Vagran | Vixidone;
(AT) Austria: Allernon | Clarityn | Lictyn | Lorano | Loratadin | Loratadin arcana | Loratadin ratiopharm | Loratadin stada artzneimittel | Loratadin-alternovaatzneimittel | Toppoll;
(AU) Australia: Alledine | Allerdyne | Allereze | Amcal loratadine | Apohealth loratadine | Apohealth loratadine hayfever & allergy relief | Blooms the chemist loratadine | Cetedyne | Chemmart loratadine | Chemplus loratadine | Children's Claratyne | Claratyne | Cm Loratadine | Demazin allergy + hayfever relief | Guardian loratadine | Lorano | Lorapaed | Lorastyne | Medihealth loratadine | Pc Loratadine | Pharmacist Formula Loratadine | Pharmacy care loratadine | Pharmacy health loratadine | Priceline loratadine | Terry white chemists loratadine | Trust Loratadine | Tw Loratadine;
(BD) Bangladesh: Alaron | Aleze | Analor | Cladin | Claritine | Din | Eladin | Elo | Encilor | Eradex | Lodin | Lora | Loradin | Lorastine | Lorat | Loratec | Loratin | Loratin-ft | Loren | Lorfast | Lorin | Noseral | Oradin | Orin | Pretin | Relor | Silora | Tide | Tirlor;
(BE) Belgium: Claritine | Loratadine bexal | Loratadine eg | Loratadine merck-generics | Loratadine Sandoz | Loratadine teva generics belgium | Sanelor;
(BF) Burkina Faso: Clarityne | Clartec | Loratol | Lorhist | Lorinol | Pretin | Tirlor;
(BG) Bulgaria: Claritine | Erolin | Loratadin | Loredin | Roletra;
(BR) Brazil: Alergaliv | Atinac | Clarilerg | Claritin | Cloratadd | Histadin | Histalor | Histamix | Lergitec | Loradine | Loralerg | Loranil | Lorasc | Lorasliv | Loratadina | Loratamed | Loremix | Loritil | Neo Loratadin;
(CH) Switzerland: Claritine | Lora Mepha Allergi | Lorado | Lorado Pollen | Loratadin Actavis | Loratadin Helvepharm | Loratadin Sandoz | Loratin Mepha;
(CI) Côte d'Ivoire: Akaryd | Allergine | Loractiv | Loractyne | Loratadine generis | Loratadine hakim | Lorhist | Lorinol | Lorix;
(CL) Chile: Alergan | Alledryl | Artamina | Clarityne | Frenaler | Histaplus | Histidanyl | Larmax | Lontadex | Loptame | Loratadina | Loretina | Primorix | Zinlergia;
(CN) China: Ao hui feng | Ao mi xin | BAI WEI LE | Bai wei tan | Bang nuo | Bi sai ning | Bi yan tong | Chang ke | Clarityne | Da sheng rui li | Fei ge man | Fu lai xi | Jing wei | Ke mi | Kui yin | Lei ning | Min li ke | Nuo ding | She tai | Shi nuo min | Shu rui | Shun ta xin | Tai ming ke | Tian qing zheng shu | Tian tu | Tianqing zheng shu | Xin da yue | Xue fei | Xue su | Yi bang | Yi fei | Yi li xin | Yi shu chang | Zhi min;
(CO) Colombia: Alatrin | Alerclar | Atadin | Cladine | Clarityne | Clarityne rapitabs | Efectine | Eutarpan | Exul | Hislort | Histabloq | Histaloran | Histapen | Loracert | Lorad | Loramine | Loratadina | Loratadina mk | Lordinex | Loreken | Lorex | Loristat | Lorydin | Noxin | Ponderal | Relergic | Rinil | Tadine | Valket;
(CZ) Czech Republic: Claritine | Erolin | Flonidan | Loranol | Loratadin | Roletra;
(DE) Germany: Clarityne | Gib Loratadin | Lisino | Lobeta gegen allergien | Lora | Lora ADGC | Lora lich | Loraderm | Loragamma | Lorano | Lorano akut | Loratadin | Loratadin acis | Loratadin akut | Loratadin axi | Loratadin axicur | Loratadin beta | Loratadin CT | Loratadin ksk | Loratadin ratiopharm bei Allergien | Loratadin Sandoz | Loratadin Stada | Loratadura | Loratagamma | Loravis;
(DK) Denmark: Loratadin alpharma | Mildin;
(DO) Dominican Republic: Aler ka | Alerin | Antial | Clarityne | Desolin | Efectine | Floginax | Frenaler | Inalor | Loragen | Loraler | Loratadina | Loratadina Calox | Loratadina lam | Loratadina quidom | Loratadina sued | Loratafran | Medilorat | Proactin | Sensibit | Sinhistan | Tabcin alergia | Tirlor | Zoman;
(EC) Ecuador: Alerfast | Alerflash | Alergin | Alergit | Alerpriv | Alervic | Aloratt | Clarityne | Efectine | Frenaler | Histaloran | Histaplus | Hysticlar | Larotin | Loratadina | Loratadina la sante | Loratadina mk | Loratadina-R | Loratin | Lorexin | Proactin | Tricel | Vilamax | Zoman;
(EE) Estonia: Claritine | Clarityn | Loradon | Loratadine actavis | Loratadine Sandoz | Loratin | Loratin express | Rinolan;
(EG) Egypt: Claritine | Histlor | Laratan | Lorano | Loraswab | Loratan | Loratin | Lorine | Mosedin | Sedclarit | Uniloratadine;
(ES) Spain: Civeran | Clarityne | Loratadina bayvit | Loratadina bexal | Loratadina cinfa | Loratadina combix | Loratadina Cuve | Loratadina davur | Loratadina kern | Loratadina Korhispana | Loratadina lasa | Loratadina normon | Loratadina Pharmagenus | Loratadina qualigen | Loratadina ranbaxy | Loratadina Ratiopharm | Loratadina rimafar | Loratadina Tamarang | Loratadina tarbis | Loratadina UR | Velodan;
(ET) Ethiopia: Claritine | Loradine | Lorastamin | Lorazim | Lorman | Mosedin | Remidine | Ticevis | Tidilor;
(FI) Finland: Clarityn | Histadin | Loradatin sandoz | Loratadin Actavis | Loratadin alpharma | Loratadin durascan | Loratadin generics | Loratadin hexal | Loratadin ratiopharm | Loratadin Sandoz | Loratadin Stada | Loraxin | Tuulix;
(FR) France: Clarityne | Doliallergie loratadine | Humex allergie loratadine | Loratadine actavis | Loratadine Almus | Loratadine Arrow | Loratadine Biogaran | Loratadine Cristers | Loratadine eg | Loratadine mylan | Loratadine Nepenthes | Loratadine Qualimed | Loratadine Ranbaxy | Loratadine Ratiopharm | Loratadine Sandoz | Loratadine Winthrop | Loratadine Zydus | Zaprilis;
(GB) United Kingdom: Asda hayfever & allergy | Boots hayfever relief all day | Clarityn | Clarityn allergy | Clarityn Rapide Allergy | Em pharma one a day allergy | Hayfever & allergy | Hayrite | Lorapaed | Loratadine cox | Loratadine kent | Loratadine Sandoz | Loratadine teva | Non drowsy allergy relief | Non drowsy hayfever & allergy relief | Roletra;
(GR) Greece: Allergofact | Biliranin | Bollinol | Clarityne | Difmedol | Helporigin | Horestyl | Latoren | Lora | Loratab | Novacloxab | Ralinet | Utel | Zelmar;
(HK) Hong Kong: Allergone | Allertyn | Allor | Ambrace | Anhissen | Apo loratadine | Carin | Clarin | Clarinet | Clarityne | Cp Loradine | Euritin | Ezede | Folerin | Genadine | Kalidin | Loranox | Loratadin | Loratadina | Loraton | Lorita | Lortin | Lorytec | Lotadine | Lotin | Natsin Day | Nt alergi | Ratadine | Rinityn | Sunadine | Synratadine | Tirlor | Uni Claritin;
(HR) Croatia: Belodin | Belodin a | Claritine | Claritine Alergija | Contral | Flonidan | Rinolan | Rinolan Alerg;
(HU) Hungary: Claritine | Claritine akut | Erolin | Flonidan | Loratadin hexal | Loratadin ratiopharm | Roletra;
(ID) Indonesia: Alerhis | Alernitis | Allohex | Alloris | Anhissen | Anlos | Clarihis | Claritin | Clarixin | Clatatin | Cronitin | Dayhist | Dinazen | Folerin | Gradine | Hislorex | Histaritin | Imunex | Inalergi | Inclarin | Klinset | Lergia | Lesidas | Logista | Loran | Lorapharm | Loratadin | Lorihis | Nosedin | Nufalora | Omellegar | Prohistin | Pylor | Rahistin | Rihest | Safetin | Sohotin | Soneryl | Tinnic | Winatin | Xepalodin | Zeos;
(IE) Ireland: Clareeze Allergy | Clarityn | Histaclar | Lorat;
(IL) Israel: Lorastine | Loratadine teva | Loratrim;
(IN) India: Alaspan | Alastin | Alerta | Algyfree | Alorti | Avil advance | Awayke | Claridin | Cozy | Eldin md | Lohist | Lomax | Lor | Loract | Loratin | Lorfast | Lorid | Loridin | Lorin | Lorinol | Lormeg | Loronet | Lorsyn | Lortab dt | Lortadin | Lotic | Olang | Rapidin | Roletra | StopAllerG | Talor | Tarol | Tirlor;
(IQ) Iraq: Aswatadin | Laritin | Loradin | Loradix | Lorasaf | Lorasam | Loratadin awa | Lorax;
(IS) Iceland: Loritin;
(IT) Italy: Alorin | Clarityn | Fristamin | Loratadina EG | Loratadina ranbaxy | Loratadina Sandoz;
(JO) Jordan: Clara | Claritine | Histal | Klarihist | Lohist | Loratan | Lorax | Loreen | Lorine | Lormine | Ramitin | Rayon | Restamine | Tidilor;
(JP) Japan: Claritin | Claritin ex | Claritin shionogi | Loratadine Amel | Loratadine ffp;
(KE) Kenya: Cetin | Claritine | Folerin | Histachlor | Loractiv | Loradine | Loraglob | Loras | Lorata | Loraten | Loratin | Loratin fast | Loratyn | Loreze | Lorfast | Lorhistina | Lorix | Lorvic | Lorytec | Lotin | Neoday | Pretin | Soloratidin | Tidilor;
(KR) Korea, Republic of: Aletin | Alleoff l | Allerno | Alleroff l | Allertadine | Alletin | Alletine | Allostop | Alostop | Claritin | Clarityne | Clarityne radi | Cleardin | Daewoo loratadine | Ejyasmin | Ethytadin | Ezasmin | Floradin | Histadin | Histafa | Histapa | J-tadine | Jeil algyssak lora | Jeratadine | Lodain | Loradine | Loragen | Loran | Loranil | Loratadine guju | Loratadine sa | Loratain | Loratin | Loratyn | Lorazin | Loridin | Nelson loratadine | Newrodine | Norapin | Noratin | Notamin | Rastadin | Sinotadine;
(KW) Kuwait: Apo loratadine | Clara | Claritine | Emilora | Klarihist | Lohist | Loracare | Loraday | Lorano | Loratan | Loratin | Loraxine | Lorine | Lorine fm | Lorytec | Mosedin | Neoday | Restamine;
(LB) Lebanon: Apo loratadine | Clara | Claritine | Histal | Loradad | Loratan | Loratin | Lorine | Oradin | Oradine | Ramitin | Restamine | Xanidin | Zifar;
(LT) Lithuania: Claritine | Erolin | Flonidan | Lomilan | Loradon | Loratadin 10-sl | Loratadin bijon | Loratadine actavis | Loratadine Alpharma | Loratadine bijon | Loratadine teva | Loratin | Loridin;
(LU) Luxembourg: Claritine | Lorano | Rupton | Sanelor;
(LV) Latvia: Claritine | Erolin | Lomilan | Loracip | Loradin | Loratadin | Loratin | Loratin express | Loridin | Rinolan;
(MA) Morocco: Allergine | Clarityne | Clartec | Histanorm | Loractine | Zifar;
(MX) Mexico: Albatrina | Alenous | Alsaltor | Aludix | Alviumito | Antilergal | Biolorat | Cilora | Clarigen | Clarityne | Clarityne zydis | Curyken | Dimegan | Ditana | Doralan | Dotagil | Efectine | Grimeral | Histina | Histox | Hl Ysta | Inigrin | Israimel | Laritol | Lertamine | Licortin | Lictyn | Liduqa | Liferamin | Loramsa | Loratadina | Loratadina farmaco | Loratadina gi kend | Loratadina gi mave | Loratadina gi serr | Loratadina Iqfa | Loratadina Landsteiner | Loratadina Loeffler | Loratadina Teva | Lotan | Lotinex | Lovarin | Lowadina | Neoalexil | Nidatar | Quimtadine | Rinard | Roletra | Sensibit | Serralsina | Simablok | Sitinir | Tadinar | Tadinose | Terentia | Urtisin | Vincidal | Zeryne;
(MY) Malaysia: Apo loratadine | Avotyne | Axcel loratadine | Carin | Clarityne | Dyna Loratadine | Ezede | Halon | Loradine | Loradyne | Lorastyne | Loratadin Stada | Loraten | Loratyn-10 | Lorazin | Loridin | Lorsedin | Rhinitin | Ridamin | Roletra | Rotifar | Sunadine | Zoratadine;
(NG) Nigeria: Afrab loratadine | Claritine | Esley loratadine | Everdestiny loratadine | Greenhope loratadine | Hanritin | Julordin | Kinratyn | Lalora | Lantine | Lorergy | Nectadine | Pinnacle loratadine | Pretadin;
(NL) Netherlands: Allerfre | Claritine | Clarityne | Kruidvat hooikoortstabletten loratadine | Loratadine Hexal | Loratadine hooikoortstabletten Apotex | Loratadine Sandoz;
(NO) Norway: Clarityn | Clarityn S | Clarityne | Loratadin | Loratadin BMM Pharma | Loratadin copyfarm | Loratadin gea | Loratadin hexal | Loratadin Orifarm | Loratadin Sandoz | Versal;
(NZ) New Zealand: Apo loratadine | Children's Claratyne | Claratyne | Lora-tabs | Loraclear | Loraclear Hayfever Relief | Lorafix | Lorfast | Pharmacy health loratadine hayfever & allergy relief;
(PE) Peru: Alerfast | Alergiatadina | Alertadin | Alertil | Alledryl | Allergy tadina | Avallert | Clarityne sp | Cronopen | Dimens | Eclaran | Efecutin | Histafren | Loralab-d | Loralerghyna | Lorastamin | Lorat | Loratadina | Loristal | Loristat | Loritex | Nasaler | Oratadina allergy | Proactin | Rinalor | Roletra | Tirlor;
(PH) Philippines: Actidin | Allergix | Allerta | Allisin | Allor | Antal | Biobril | Carin | Clarihist | Claritin | Histadine | Immunix | Laradin | Lergicyl | Loaller | Loradex | Loradine | Lorafix | Lorahist | Lorange | Lorano | Lorarex | Lorat | Lordam | Lordamin | Lorexa | Lorfast | Lorid | Onemin | Prevahist | Rinityn | Rm loratadine | Sylergy | Toral | Zylohist;
(PK) Pakistan: Al care | Alavert | Alerde | Alerfree | Alertine | Alerway | Allerget | Allerwood | Allorat | Alor | Alten | Andin | Antial | Antimin | Axalor | Baxadin | Cara gix | Celestin | Claritine | Clarix | Clazine | Clintal | Clintol | Conrat | Dinclor | Dinsave | Ezitine | Floret | Fozil | Frend | Gollergic | Haylief | Hico-od | Hispar | Hisplex | Histadine | Histamac | Histanil | Histar | Historat | Jade | Korat | Laraib | Leksus | Lohist | Loin | Lolergy | Lor | Loradine | Loragix | Loramax | Loramed | Loranees | Loratad | Loratamed | Loratascot | Lorate | Lorated | Loratine | Loratlax | Loratop | Lorazid | Lorcet | Lordin | Lorefect | Lorel | Lorex | Lorid | Lorin-nsa | Lornas | Lortab | Lortamine | Lortec | Lortin | Lortin D | Losad | Lotad | Lotin | Lumfort | Mastal | Maxotel | Megalor | Momtek | Mydin | Nonsed | Notres | P-Lor | P-sur | Relent | Resotin | Rhilor | Rhinamin | Rudin | Sedinor | Selectin | Selordine | Senergy od | Sinease | Softin | Synadin | Talergin | Tavelor | Teldrin | Telkot | Texcol allergy | Tirlor | Urti-Care | Velair | Verat | Victrin | Widine | Xylor | Zestress | Zorat | Zordin;
(PL) Poland: Alerfan | Aleric | Claritine | Claritine allergy | Claritine spe | Flonidan | Flonidan control | Lorahexal | Loram | Loratadine 1A Pharma | Loratadyna | Loratadyna Pylox | Loratan | Loratine | Nalergine | Rotadin;
(PR) Puerto Rico: Alavert | Allergy Relief | Children's Claritin | Children's loratadine | Claritin | Claritin Hives Relief | Claritin Reditabs | Clear-Atadine | Tavist nd;
(PT) Portugal: Alertrin | Claritine | Loratadina | Loratadina mylan;
(PY) Paraguay: Alercrom | Biloina | Clarityne | Histafren | Lontadex | Loraler | Loratadina bilac | Loratadina cellofarm | Loratadina dallas | Loratadina kirei | Loratadina la sante | Paralergim | Sinaler;
(QA) Qatar: Clara (Jamjoom) | Claritine | Emilora | Klarihist | Lohist | Loradad | Loraday | Loradox | Loramax | Lorano | Loratin | Loreen | Lorine | Lorine FM | Neoday | Oradine | Ramitin | Rayon | Restamine | Tidilor;
(RO) Romania: Claritine | Erolin | Flonidan | Latoren | Lorastamin | Loratadina biofarm | Loratadina sintofarm | Loratadina slavia | Loratan | Symphoral;
(RU) Russian Federation: Alerpriv | Clargotil | Clarifarm | Clarifer | Clarisens | Claritine | Clarnedin | Clarotadin | Clarotadine | Erolin | Klallergin | Klallergine | Klarfast | Klaridol | Klarifer | Klarisens | Lomilan | Loradin | Lorahexal | Loratadine eco | Loratadine hemofarm | Loratadine stada | Loratadine teva | Loratadine vertex | Loratadinum kmp | Loratavel | Loratin | Loridin | Vero loratadine;
(SA) Saudi Arabia: Apo loratadine | Clara | Claritine | Glora | Lohist | Lojour | Loraday | Lorahist | Loramax | Lorano | Loratin | Lorine | Neoday | Ramitin | Restamine | Tidilor;
(SE) Sweden: Clarityn | Clarityn S | Loratadin 2care4 | Loratadin abece | Loratadin Actavis | Loratadin Apofri | Loratadin BMM Pharma | Loratadin copyfarm | Loratadin hexal | Loratadin Mylan | Loratadin Orifarm | Loratadin ratiopharm | Loratadin Sandoz | Loratadin Stada | Versal;
(SG) Singapore: Allertyn | Clarityne | Ezede | Halodin | Histalor | Loradine | Loratyn | Lorfast | Loridin | Ridamin | Rinityn | Roletra;
(SI) Slovenia: Claritine | Claritine S | Flonidan | Flonidan S | Rinolan;
(SK) Slovakia: Claritine | Erolin | Flonidan | Loranol | Loratadin | Restamine | Rinolan;
(TH) Thailand: Alertyne | Aller-tab tab | Allerdine | Allernix | Allersil | Allex | Aridine | Atloftin | Botidine | Cantadine | Caradine | Carinose | Cetyne | Clalergy | Clalodine | Clarid | Claridine | Clarine | Claritex | Claritino | Clarityne | Clatidyne | Clatidyne O | Cloresian | Daytadine | Faradin | Fatyne | Gaprodine | Halodin | Hisracon | Histadine | Kalidin | Klaryne | Lindine | Linityne | Logadine | Loracine | Loradine | Loragis | Loramed | Loramex | Loranox | Loratyne | Lordamin | Lordin | Loridin | Lorinase | Lorita | Lorityne | Lorsedin | Lortadine | Lortec | Lotidyne | Moradine | Piptaryne | Ridamin | Rityne | Roletra | Sanotyne | Soratadine | Startyne | Talidene | Taridine | Tiradine | Tirlor | Villergy;
(TN) Tunisia: Clarityne | Histadine | Loradine | Oramine | Restamine;
(TR) Turkey: Alarin | Allertidin | Antor | Claritine | Hismen | Histadin | Klodin | Loradif | Lorateva | Loritine | Ritin;
(TW) Taiwan: Besumin | Clarityne | Clatine | Finska | Fucole Minlife | Genadine | Lomidine | Lora | Loradin | Lorastyne | Loratyn | Lorchimin | Losta | Lotarin | Minlife | Mintapp | Rodamine;
(UA) Ukraine: Agistam | Aleric | Claridol | Claritine | Erolin | Flonidan | Klarifer | Lorano | Loratadin | Loratadine sl | Lorfast | Loridin rapid | Lorizan;
(UG) Uganda: Antimin | Axcel loratadine | Claritine | Klarol | Loras | Lorased | Lorhistina | Loridin | Lorytec | Lumfort | Mosedin;
(UY) Uruguay: Alerfast | Alergipan | Alerton | Biloina | Clarityne | Efecutin | Flodin NF | Frenaler | Frenistal | Hisplex | Hisradin | Loratadina | Loratadina Pellier | Loratil;
(VE) Venezuela, Bolivarian Republic of: Alerdina | Alertidine | Clarityne | Loradex | Loradin | Loratadina | Loraval | Lorex | Loriden | Lotal | Polaramine reformulado | Proactin | Roletra | Sitadin | Tirlor;
(VN) Viet Nam: Agilodin | Axota | Bolorate | Clanoz | Eftilora | Ganusa | Hamistyl | Lohatidine | Lorabay | Loradil | Lorastad | Lortalesvi | Roustadin | Usalota | Usarad | Ustadin | Vaco loratadine;
(ZA) South Africa: Allergex non drowsy | Ap Loratadine | Apex Loratadine | Cipla Loratadine | Clarinese | Clarityne | Demazin anti-allergy | Laura | Lorahist | Lorano | Loratadine biotech | Loratyne | Lormeg | Pollentyme | Rhinigine | Rolab-loratadine;
(ZM) Zambia: Allerban | Allerdin | Claritine | Lorano | Loratan | Loridin | Lormeg | Pollentyme | Pollentyme s;
(ZW) Zimbabwe: Axcel loratidine | Lorano | Loratin

Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. J Pediatr. 2001;139(2):317-319. [PubMed 11487763]
Alavert (loratadine) [prescribing information]. New York, NY: Pfizer Consumer Healthcare; no date.
American Academy of Pediatrics (AAP). Cough and cold medicines should not be prescribed, recommended or used for respiratory illnesses in young children. Updated June 12, 2018. http://www.choosingwisely.org/clinician-lists/american-academy-pediatrics-cough-and-cold-medicines-for-children-under-four.
Anderson PO, Sauberan JB. Modeling drug passage into human milk. Clin Pharmacol Ther. 2016;100(1):42-52. [PubMed 27060684]
Aronoff GR, Bennett WM, Berns JS, et al. Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children. 5th ed. Philadelphia, PA: American College of Physicians; 2007:95-168.
Asero R. New-onset urticaria. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed November 23, 2021.
Butler DC, Heller MM, Murase JE. Safety of dermatologic medications in pregnancy and lactation: Part II. Lactation. J Am Acad Dermatol. 2014;70(3):417. [PubMed 24528912]
Centers for Disease Control and Prevention (CDC). Infant deaths associated with cough and cold medications--two states, 2005. MMWR Morb Mortal Wkly Rep. 2007;56(1):1-4. [PubMed 17218934]
Centers for Disease Control and Prevention (CDC). Neonatal deaths associated with use of benzyl alcohol—United States. MMWR Morb Mortal Wkly Rep. 1982;31(22):290-291. http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm. [PubMed 6810084]
Children's Claritin Allergy (loratadine) [prescribing information]. Whippany, NJ: Bayer Healthcare LLC; 2017.
Claritin Chewables (loratadine) [prescribing information]. Whippany, NJ: Bayer HealthCare LLC; received June 2022.
Claritin Children's Chewables (loratadine) [prescribing information]. Whippany, NJ: Bayer HealthCare LLC; received January 2023.
Claritin Syrup (loratadine) [package insert]. Kenilworth, NJ: Schering Corporation; July 2000.
Claritin tablets (loratadine) [prescribing information]. Whippany, NJ: Bayer HealthCare LLC; 2020.
Claritin tablets, syrup, rapidly-disintegrating tablets (loratadine) [product information]. Kenilworth, NJ: Schering Corporation; September 2000.
Haria M, Fitton A, Peters DH. Loratadine: a reappraisal of its pharmacological properties and therapeutic use in allergic disorders. Drugs. 1994; 48(4):617-637. [PubMed 7528133]
Hilbert J, Radwanski E, Affrime MB, et al. Excretion of loratadine in human breast milk. J Clin Pharmacol. 1988;28(3):234-239. [PubMed 2966185]
"Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics (AAP) Committee on Drugs. Pediatrics. 1997;99(2):268-278. [PubMed 9024461]
Ito S. Drug therapy for breast-feeding women. N Engl J Med. 2000;343(2):118-126. [PubMed 10891521]
Ito S, Blajchman A, Stephenson M, et al. Prospective follow-up of adverse reactions in breast-fed infants exposed to maternal medication. Am J Obstet Gynecol. 1993;168(5):1393-1399. [PubMed 8498418]
Khan DA. Chronic spontaneous urticaria: standard management and patient education. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed November 23, 2021.
Kliegman RM and St. Geme J, eds. Nelson Textbook of Pediatrics. 21st ed. Philadelphia, PA: Saunders Elsevier; 2020.
Loradamed [package insert]. Fort Myers, FL: Medique Products; May 2007.
Matzke GR, Halstenson CE, Opsahl JA, et al. Pharmacokinetics of loratadine in patients with renal insufficiency. J Clin Pharmacol. 1990;30(4):364-371. doi:10.1002/j.1552-4604.1990.tb03607.x [PubMed 2140371]
Messinis IE, Souvatzoglou A, Fais N, Lolis D. Histamine H1 receptor participation in the control of prolactin secretion in postpartum. J Endocrinol Invest. 1985;8(2):143-146. [PubMed 3928731]
Powell RJ, Leech SC, Till S, et al. BSACI guideline for the management of chronic urticaria and angioedema. Clin Exp Allergy. 2015;45(3):547-565. [PubMed 25711134]
Pozzo-Magaña BR. Chronic urticaria in children: a review. EMJ Dermatol. 2017;5(1):74-82.
Scadding GK, Kariyawasam HH, Scadding G, et al. BSACI guideline for the diagnosis and management of allergic and non-allergic rhinitis (revised edition 2017; first edition 2007). Clin Exp Allergy. 2017;47(7):856-889.
Simons FE, Simons KJ. The pharmacology and use of H1-receptor-antagonist drugs. N Engl J Med. 1994;330(23):1663-1670. [PubMed 7909915]
US Food and Drug Administration (FDA). Most young children with a cough or cold don't need medicines. https://www.fda.gov/ForConsumers/ConsumerUpdates/ucm422465.htm. Published July 18, 2017. Accessed November 2, 2018.
US Food and Drug Administration (FDA). Use caution when giving cough and cold products to kids. https://www.fda.gov/drugs/resourcesforyou/specialfeatures/ucm263948.htm. Updated February 8, 2018. Accessed November 2, 2018.
Zuberbier T, Aberer W, Asero R, et al. The EAACI/GA²LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria. Allergy. 2018;73(7):1393-1414. [PubMed 29336054]

Topic 12563 Version 752.0

خرید پکیج

Loratadine: Pediatric drug information